Agile Therapeutics (NASDAQ:AGRX) Stock Price Down 37.4%

Agile Therapeutics Inc (NASDAQ:AGRX)’s share price traded down 37.4% during mid-day trading on Friday . The stock traded as low as $1.40 and last traded at $1.49, 17,307,500 shares changed hands during mid-day trading. An increase of 930% from the average session volume of 1,679,968 shares. The stock had previously closed at $2.38.

Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Maxim Group reiterated a “buy” rating on shares of Agile Therapeutics in a report on Friday, November 1st. ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. Royal Bank of Canada increased their price objective on shares of Agile Therapeutics to $5.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, William Blair upgraded shares of Agile Therapeutics from a “market perform” rating to an “outperform” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $3.75.

The stock has a market capitalization of $131.06 million, a P/E ratio of -2.57 and a beta of 0.39. The stock’s fifty day moving average is $1.33 and its two-hundred day moving average is $1.30.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, October 28th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.08). As a group, equities analysts forecast that Agile Therapeutics Inc will post -0.36 earnings per share for the current fiscal year.

In related news, major shareholder Perceptive Advisors Llc sold 3,815,349 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $0.51, for a total transaction of $1,945,827.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.50% of the company’s stock.

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 7.9% in the 2nd quarter. Acadian Asset Management LLC now owns 450,180 shares of the specialty pharmaceutical company’s stock valued at $657,000 after acquiring an additional 32,911 shares in the last quarter. BlackRock Inc. lifted its position in shares of Agile Therapeutics by 27.2% in the 2nd quarter. BlackRock Inc. now owns 169,226 shares of the specialty pharmaceutical company’s stock valued at $247,000 after acquiring an additional 36,212 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock valued at $108,000 after acquiring an additional 73,238 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock valued at $3,291,000 after acquiring an additional 120,403 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after acquiring an additional 978,672 shares in the last quarter. Hedge funds and other institutional investors own 33.07% of the company’s stock.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Article: Penny Stocks, What You Need To Know

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.